Home  »  Markets Briefing   »  Stocks of Coivid Vaccine Biotech Forms Start The W...

Stocks of Coivid Vaccine Biotech Forms Start The Week With Mix Reaction

Nearly all the companies in the S&P 500 have now released their results for the third quarter, with positive surprises in terms of earnings for 84 percent of them. Ultimately, the earnings of the S&P 500 decreased by 6.3 percent in the third quarter relative to the same time in 2019, while analysts predicted a 21 percent decline at the end of September. The biggest declines were suffered in detail by three sectors: electricity, air transport and hotels/restaurants, both of which were plagued by the coronavirus crisis. Except these industries, profits were up 4.3% year-on-year, driven primarily by the healthcare sector (up 13%), as well as internet services, software, biotechnology, but also the automotive industry.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


On Monday, stocks of biotech firms especially involved in coronavirus vaccines traded in distributed order, including Astrazeneca Plc (AZN) down -1% on Wall Street, Pfizer Inc (PFE) lost -0.5%, BioNTech SE (BNTX) jumped up 2.3% on Wall Street, Moderna Inc (MRNA) surged 3.5% and Curevac N.V. Inc (CVAC) gained 6.7%.

The New Jersey laboratory, Merck & Co., Inc. (MRK) was down -0.2 percent at first session of the week as it has confirmed the $425 million acquisition of OncoImmune, which produces a medication that can alleviate symptoms of Covid and minimize deaths in patients with serious types.

Regeneron Pharmaceuticals Inc. (REGN) started the week with a rise of 0.97% on Monday. Emergency use authorization has been issued by the FDA to treat Covid-19 with a combination of antibodies developed by the community. During his hospitalization following coronavirus infection in October, President Donald Trump was given the treatment. For mild to moderate cases in adults following good results, the use of the medication was approved. In early November, the FDA had already approved the treatment of Eli Lilly for newly infected patients at risk of developing a serious form of the disease.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

Sign up for Our Newsletter Now! Discover which stocks to trade!
100% Free. Stop Anytime. No Spam